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ABSTRACT
Background and Objectives: Efonidipine hydrochloride, an L- and T-type dual calcium channel blocker, is suggested to 
have a heart rate (HR)-slowing action in addition to a blood pressure (BP)-lowering effect. The aim of this study was to de-
termine the effect of efonidipine on HR and BP in patients with mild-to-moderate hypertension. Subjects and Methods: 
In a multi-center, prospective, open-labeled, single-armed study, we enrolled 53 patients who had mild-to-moderate hyper-
tension {sitting diastolic BP (SiDBP) 90-110 mmHg}. After a 2-week washout, eligible patients were treated with efonidipine 
(40 mg once daily for 12 weeks). The primary end point was the change in HR from baseline to week 12. The secondary end-
point included the change in trough sitting BP and 24-hour mean BP between baseline and week 12. Laboratory and clinical 
adverse events were monitored at each study visit (4, 8, and 12 weeks). Results: Fifty-two patients were included in the inten-
tion-to-treat analysis. After 12 weeks of treatment with efonidipine, the resting HR decreased significantly from baseline to 
week 12 {from 81.5±5.3 to 71.8±9.9 beats/minute (difference, -9.9±9.0 beats/minute), p<0.0001}. The trough BP {sitting 
systolic blood pressure (SiSBP) and SiDBP} and 24-hour mean BP also decreased significantly (SiSBP: from 144.6±8.2 to 
132.9±13.5 mmHg, p<0.0001; SiDBP: from 96.9±5.4 to 88.3±8.6 mmHg, p<0.0001, 24-hour mean systolic BP: from 
140.4±13.5 to 133.8±11.6 mmHg, p<0.0001; 24-hour mean diastolic BP: from 91.7±8.7 to 87.5±9.5 mmHg, p<0.0001). Con-
clusion: Efonidipine was effective in controlling both HR and BP in patients with mild-to-moderate hypertension. (Korean 
Circ J 2010;40:514-519)
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Introduction
Efonidipine hydrochloride, a new generation dihydropyri-
dine (DHP) calcium channel blocker, inhibits both T-type 
and L-type calcium channels.
1) Typical DHP calcium antago-
nists, such as nifedipine and amlodipine, selectively inhibit L-
type calcium channels of vascular smooth muscle cells, result-
ing in vasodilation. In addition to exhibiting an antihyper-
tensive effect through vasodilation by blocking L-type calcium 
channels, efonidipine hydrochloride has also been suggested 
to regulate heart rate (HR) by inhibiting the T-type calcium ch-
annels, which are localized primarily in the sinoatrial node Il-Young Oh, et al.   515
and are involved in the pacemaker mechanism of the heart.
2)
Furthermore, efonidipine has been reported to have a neg-
ative chronotropic effect, which may be involved in control-
ling tachycardia.
3) Working on sinoatrial node cells by inhib-
iting T-type calcium channel activation, efonidipine prolongs 
the late phase-4 depolarization of the sinoatrial node action 
potential, which suppresses an elevated HR. Previous studies 
have shown that efonidipine decreased the HR in contrast with 
other DHPs in patients with essential hypertension.
4)5)
Recent epidemiologic studies have confirmed earlier stud-
ies that showed resting HR to be an independent predictor of 
cardiovascular and all-cause mortality, independent of gen-
der or pre-existing cardiovascular disease.
6)7) Clinical trial 
results also suggest that reduction in HR alone is an impor-
tant benefit afforded by beta-blockers in patients with angi-
na pectoris, acute myocardial infarction, and chronic heart 
failure. 
Regarding hypertension treatment, an approved consen-
sus guideline has recommended antihypertensive medica-
tion with HR-lowering properties, especially in females and 
the elderly.
8) The aim of this study was to determine the effect 
of efonidipine on HR and blood pressure (BP) in patients with 
mild-to-moderate essential hypertension.
Subjects and Methods
Patients and study design
This study was performed with a multi-center, prospective, 
open-labeled, single-armed design at seven sites in the Re-
public of Korea. Men and women were eligible if they were 18-
80 years of age, had mild-to-moderate hypertension with a 
sitting diastolic BP (SiDBP) between 90 and 110 mmHg, a HR 
<75 beats/minute, and agreed to participate in the study. The 
Framingham study
9) showed that subjects with a HR >75 beats/ 
minute had higher incidence of and morbidity from cardio-
vascular disease than subjects with a HR <75 beats/minute. Thus, 
we planned to evaluate the negative chronotropic effect of efo-
nidipine in patients with a HR >75 beats/minute. 
Patients were excluded if they had severe hypertension {sit-
ting systolic BP (SiSBP) ≥180 mmHg}, a difference in BP be-
tween two arms >20 mmHg (SiSBP) or >10 mmHg (SiDBP), 
a history of stroke or myocardial infarction in the previous 6 
months, severe congestive heart failure, sick sinus syndrome 
or sinus bradycardia (<50 beats/minute), second- or third-
degree atrioventricular block, documented hypersensitivity 
to DHP or efonidipine hydrochloride, hepatic disease with 
aspartate aminotransferase (AST) or alanine aminotransfer-
ase (ALT) >2 times the upper normal limit, renal disease with 
a serum creatinine concentration >2.0 mg/dL, uncontrolled 
diabetes (hemoglobin A1C >9%), renal artery stenosis, or se-
condary hypertension. Women who were pregnant or breast-
feeding, or who were not using an effective method of con-
traception, were excluded from the study. All patients gave 
written informed consent and the institutional review board 
at each center approved this study.
The study consisted of initial screening, a 2-week washout 
period, and a 12-week active treatment period. Complete 
medical history, physical examination, and laboratory tests 
were evaluated during the initial screening.
After the 2-week washout period of previous antihyper-
tensive medications, patients were given 40 mg efonidipine 
at 8:00 a.m. (±2 hours). If the SiSBP was >140 mmHg or the 
SiDBP was >90 mmHg at 4 or 8 weeks, the dosage of efoni-
dipine was increased up to 60 mg once daily. Clinical follow-
up was performed at 4, 8, and 12 weeks of treatment. At 
each visit, the SiSBP, SiDBP, and pulse rate were measured. 
The resting HR was measured manually for 1 minute after 
the patient had rested in a sitting position for 30 minutes. 
The BP was measured as follows: the same time of day, be-
fore dosing, the same arm, by the same investigator at each 
center, and using mercury sphygmomanometers manufac-
tured by one company (W.A. Baum Co. Inc., Copiague, NY, 
USA).
10) Ambulatory BP monitoring (ABPM) was performed 
twice at baseline and at the end of the 12-week treatment. At 
each visit, patients were asked about adverse events (AEs). The 
treatment schedule is summarized in Fig. 1.
Efficacy and safety variables
The primary efficacy variable was the mean change in rest-
ing HR from baseline to week 12. The secondary efficacy vari-
ables included the change from baseline of the mean office tr-
ough BP (i.e., 24 hours after the last dosing) and the 24-hour 
mean BP assessed with ABPM after 12 weeks. The response 
rate was defined as the proportion of patients in which the Si-
Screening/Washout Efonidipine 40 mg/d Efonidipine 40 mg/d
If SiSBP ≥140 mmHg or SiDBP  
≥90 mmHg or SiDBP did not  
decrease by 10 mmHg, efonidipine  
dose increased to 60 mg/d 
Efonidipine 40 mg/d
If SiSBP ≥140 mmHg or SiDBP  
≥90 mmHg or SiDBP did not  
decrease by 10 mmHg, efonidipine  
dose increased to 60 mg/d
Visit 1
(week -2)
Visit 2
(day 0)
Fig. 1. Study design. SiSBP: sitting systolic blood pressure, SiDBP: sitting diastolic blood pressure. 
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DBP was <90 mmHg or had decreased by ≥10 mmHg from 
baseline after 12 weeks of treatment. Tolerability was assessed 
based on the incidence of AEs. Medical history was updated 
and laboratory tests were performed at each study visit. All lab-
oratory and clinical AEs were assessed by the investigators 
in terms of their relationship to the study drug and intensity. 
Serious AEs were defined as those that were life-threatening, 
required hospitalization, or were associated with significant 
permanent disability or congenital malformation.
Statistical analysis
A sample size of 42 patients was calculated to provide 90% 
power to detect a 5 beat/minute difference between baseline 
and 12 weeks at a significance level of α=0.05, assuming a 
standard deviation of 10 beats/minute. Based on a 20% pre-
dicted dropout rate, a sample size of 53 patients was required.
For the primary and secondary outcomes, intention-to-treat 
(ITT) and per protocol (PP) analyses were done. The ITT an-
alysis included all patients who received ≥1 dose of study me-
dication, had a valid resting HR and BP measurement at 
baseline, and had ≥1 valid HR and BP measurements after 
baseline, with missed observations imputed using the last-
observation-carried-forward method. Patients with protocol 
violations and those with <75% compliance were excluded 
from the PP analysis. For statistical analyses of the primary and 
secondary endpoints, a paired t-test was used.
For a comparison of baseline characteristics, continuous 
variables were compared using a t-test and analysis of covari-
ance, and discrete variables were compared using a χ2 test. 
Differences were considered statistically significant at a p< 
0.05. All data analyses were performed using the Statistical 
Package for the Social Sciences (SPSS), version 13.0 (SPSS Inc., 
Chicago, IL, USA).
Results
Patient disposition
Sixty-three patients were screened. Eleven patients were 
not eligible for this study and 52 patients were enrolled in the 
study. After enrollment, one patient had never taken one dose 
of efonidipine, and was excluded from the ITT analysis. Thus, 
52 patients were included in the ITT analysis. The PP analy-
sis included 39 patients; 13 patients were excluded from the 
PP analysis due to AEs (7 patients) that included palpitations, 
hot flushes, nausea, headaches, dyspepsia, withdrawal of con-
sent (2 patients), protocol violations (1 patient), and lost to 
follow-up (2 patients). The disposition of study patients was sum-
marized in Fig. 2. The baseline characteristics of the enrolled pa-
tients were summarized in Table 1.
63 patients assessed
11 patients not eligible
7 drop out due to adverse effects
3 consent withdrawal
1 major protocol violation
2 follow-up loss
53 patients enrolled
efonidipine 40 mg daily
52 included in intention-to-treat analysis
39 included in per-protocol analysis
1 not taking efonidipine at all
Fig. 2. Disposition of study patients.
Table 1. Baseline demographic and clinical characteristics of Ko-
rean patients with mild-to-moderate essential hypertension
Characteristic
Male 
(n=36)
Female 
(n=16)
p
Age (years) 0.5552
Mean 046.9±9.6 048.8±13.1
Range 31.0-65.0 28.0-70.0
Height (cm) <0.0001
Mean 170.3±4.9 154.8±7.4
Range 157.5-180.7 139.5-169.7
Body weight (kg) <0.0001
Mean 073.2±9.3 057.3 ±11.7
Range 58.0-108.0 34.0-86.4
Blood pressure (mmHg)
SiSBP 0.8329
Mean 144.8±7.8 144.3±9.3
Range 131.0-163.0 131.0-160.0
SiDBP 0.0518
Mean 097.9±5.5 094.8±4.6
Range 90.0-109.0 90.0-105.0
Smoking, no. (%) <0.0001
None 06 (16.7) 14 (82.4)
Previous 10 (27.8) 00 (0.0)0
Habitual 20 (55.6) 03 (17.7)
Alcohol use, no. (%) 31 (86.1) 06 (35.2) 0.0002
Previous use of 
  antihypertensives, no. (%)
05 (13.9) 02 (11.8) 0.8312
Glucose (mg/dL) 093.7±7.7 92.0±7.2 0.4519
Creatinine (mg/dL) 001.0±0.1 00.7±0.1 <0.0001
Total cholesterol (mg/dL) 0195.5±27.1 192.0±23.4 0.9465
SiSBP: sitting systolic blood pressure, SiDBP: sitting diastolic blood 
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Change in heart rate from baseline
The primary end point, the mean change in resting HR from 
baseline to week 12, was analyzed in the ITT and PP groups. 
Based on the ITT analysis, the resting HR decreased signifi-
cantly from baseline to week 12 {from 81.5±5.3 to 71.8±9.9 
beats/minute (difference, -9.9±9.0), p<0.0001} (Table 2). 
Based on the PP analysis, the resting HR also decreased sig-
nificantly {from 81.1±5.2 to 69.5±8.4 beats/minute (difference, 
-11.6±8.1), p<0.0001}. In both the ITT and PP groups, the de-
crease in HR was maintained during the 12-week treatment 
period with efonidipine (Fig. 3).
Change in blood pressure from baseline
The trough SiSBP and SiDBP decreased significantly from 
baseline to week 12 in both ITT and PP analyses {ITT (SiSBP), 
from 144.6± to 132.9± mmHg, p<0.0001; ITT (SiDBP), from 
96.9± to 88.3± mmHg, p<0.0001; PP (SiSBP), from 144.2± 
to 131.3± mmHg, p<0.0001; PP (SiDBP), from 96.7± to 87.7± 
mmHg, p<0.0001}. The 24-hour ambulatory mean SBP and 
DBP also decreased significantly in both IIT and PP analyses 
{ITT (ABPM SBP), from 140.4±13.5 to 133.8±11.6 mmHg, 
p<0.0001; ITT (ABPM DBP), from 91.7±8.7 to 87.5±9.5 
mmHg, p<0.0001; PP (ABPM SBP), from 139.6±11.9 to 133.5± 
11.7 mmHg, p<0.0001; PP (ABPM DBP), from 91.5±8.8 to 
87.5±9.6 mmHg, p<0.0001}. 
Response rates
The response rates were 66.7% (32/44) for the trough SiDBP 
and 65.8% (25/38) for the 24-hour ambulatory mean SiDBP.
Tolerability
There was no significant difference in the vital signs between 
baseline and 12 weeks, except the respiratory rate. The respi-
ratory rate was slightly increased (from 19.2±1.8 to 19.7±1.7 
Table 2. Changes in heart rate, trough SiSBP/SiDBP, and 24-hour ambulatory mean SBP/DBP from baseline to the end of treatment (week 
12) with efonidipine
Baseline Week 12 Difference p
Heart rate (beats/minute)
Intention-to-treat 81.5±5.3 (n=52) 71.8±9.9 (n=48) -9.9±9.0 <0.0001
Per-protocol 81.1±5.2 (n=39) 69.5±8.4 (n=39) -11.6±8.10 <0.0001
Trough SiSBP (mmHg)
Intention-to-treat 144.6±8.2 (n=52)0 132.9±13.5 (n=48) -11.9±12.9 <0.0001
Per-protocol 144.2±7.9 (n=39)0 131.3±13.1 (n=39) -12.8±12.5 <0.0001
Trough SiDBP (mmHg)
Intention-to-treat 96.9±5.4 (n=52) 88.3±8.6 (n=48) -8.8±7.7 <0.0001
Per-protocol 96.7±5.3 (n=39) 87.7±8.7 (n=39) -9.0±7.8 <0.0001
24-hour ambulatory mean SBP (mmHg)
Intention-to-treat 140.4±13.5 (n=52) 133.8±11.6 (n=38) 0-7.5±11.2 <0.0001
Per-protocol 139.6±11.9 (n=39) 133.5±11.7 (n=37) 0-6.7±10.1 <0.0001
24-hour ambulatory mean DBP (mmHg)
Intention-to-treat 91.7±8.7 (n=52) 87.5±9.5 (n=38) -4.3±7.2 <0.0001
Per-protocol 91.5±8.8 (n=39) 87.5±9.6 (n=37) -4.5±7.2 <0.0001
24-hour pulse pressure (mmHg)
Intention-to-treat 48.5±11.3 (n=52) 46.3±7.4 (n=38) -3.0±9.5 <0.0584
Per-protocol 47.8±8.5 (n=39)0 45.9±7.2 (n=37) -7.3±9.4 <0.0919
Non-dipper, N (%)
Intention-to-treat 30/52 (57.7)  17/38 (44.7)
Per-protocol 22/39 (56.4) 16/37 (43.2)
SiDBP: sitting diastolic blood pressure, SiSBP: sitting systolic blood pressure, SBP: systolic blood pressure, DBP: diastolic blood pressure
Fig. 3. Effects of efonidipine on heart rate at 4, 8, and 12 weeks. The 
reduction in heart rate was maintained during the active treatment 
period. ITT: intention-to-treat, PP: per-protocol. 
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breaths/minute, p<0.05), but these changes were considered 
clinically insignificant. There was no significant difference in 
the laboratory findings between baseline and 12 weeks.
No treatment-related serious AEs requiring admission were 
observed. One patient was admitted to the hospital because 
of a ventral hernia that was considered unrelated to the study 
drug. Among the 52 patients, 30 AEs were observed in 17 
patients (32.7%). Eighteen AEs in 8 patients (15.4%) were 
considered treatment-related. The most common AE was pal-
pitations (6 patients), followed by facial flushing (3 patients), 
nausea (2 patients), dyspepsia (2 patients), headaches (2 pa-
tients), chest pain (1 patient), dyspnea (1 patient), and a pur-
puric rash (1 patient). Seven patients discontinued the study 
due to AEs.
Discussion
We have confirmed that efonidipine (40-60 mg) treatment 
significantly reduced the HR by 11.9% in patients with mild-
to-moderate essential hypertension. Efonidipine also de-
creased the trough systolic and diastolic BP by 11.7 and 8.6 
mmHg, respectively. Efonidipine was well-tolerated.
A significant association between resting HR and all-
cause and cardiovascular mortality has been reported in nu-
merous epidemiologic studies and pertains to the general 
population as well as patients with various cardiovascular 
diseases, including hypertension, acute myocardial infarction, 
and heart failure.
11)12) 
In spite of excellent BP-lowering properties, the use of DHP 
calcium channel blockers is sometimes limited in patients 
with angina or myocardial infarction due to acceleration of 
the HR.
13-17) DHPs mainly block L-type calcium channels of 
blood vessels,
18)19) which induces vasodilation, thus quickly 
reducing the BP, but easily causes compensatory sympathet-
ic activation, increasing the HR and cardiac oxygen demand.
However, efonidipine, which blocks both T-type and L-type 
calcium channels, has been reported to decrease the HR in 
several conditions. Morimoto et al.
20) showed that efonidipine 
inhibits an increase in HR and BP due to stress, presumably 
by blocking T-type calcium channels rather than by inhibit-
ing the sympathetic nervous system. Tanaka et al.
4) showed 
that efonidipine decreases the HR and plasma aldosterone 
more than amlodipine in patients with hypertension. Fur-
thermore, this negative chronotropic effect has been suggest-
ed to exert an anti-arrhythmic action. Kinoshita et al.
21) dem-
onstrated that efonidipine reduces arrhythmias and sudden 
death in a mouse model of dilated cardiomyopathy by repo-
larizing the resting membrane potential and normalizing the 
cardiac autonomic nervous system imbalance. These findings 
suggest potential therapeutic applications for efonidipine as 
an antihypertensive agent for patients at high risk for fatal ar-
rhythmias and sudden death, such as patients with severe he-
art failure.
Currently, the role of beta-blockers as first-line antihyper-
tensives has been challenged.
22) A meta-analysis by Lindholm 
et al.
23) suggested that the risk of stroke was 16% higher with 
beta-blockers than with other drugs and the risk of all-cause 
mortality was 3% higher. In fact, beta-blockers were exclud-
ed from routine initial therapy for hypertension in the 2006 
British Hypertension Society guidelines. However, the HR-
lowering effect of beta-blockers is still required in certain hy-
pertensive patients, such as those with high sympathetic ac-
tivity.
Our findings suggest that efonidipine might be a better al-
ternative to beta-blockers as an initial antihypertensive medi-
cation. In this study, once daily efonidipine was effective not 
only in the control of mild-to-moderate hypertension, but 
also in the reduction of HR, which is significantly associated 
with clinical outcome in hypertension.
24) Finally, a 12-week 
course of treatment with efonidipine was well-tolerated and 
no treatment-related serious AEs occurred.
There were several limitations to this study. First, this was 
an open-label, single-arm, uncontrolled study. Owing to ethi-
cal perspectives concerning non-antihypertensive therapy in 
patients with confirmed hypertension, we were unable to cre-
ate a control group. To reduce the observer-dependent bias, 
we measured not only the official trough BP, but also the am-
bulatory 24-hour mean BP. Second, the number of enrolled 
patients was too small to extrapolate to the broader popula-
tion. However, our results were consistent with the previous 
pilot study
5) which was done in 18 patients with mild-to-
moderate hypertension. This finding suggests that the bene-
ficial effects of efonidipine on HR and BP exist.
In conclusion, efonidipine can safely decrease BP with a re-
duction in HR in patients with mild-to-moderate hyperten-
sion. There results suggest that efonidipine may be therapeu-
tically useful as an initial agent for essential hypertension.
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